Thermo Fisher Scientific CD18 Monoclonal Antibody (2E6)

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

Assay-dependent

-

Immunoprecipitation (IP)

Assay-dependent

-

Neutralization (Neu)

-

View 4 publications 4 publications

Inhibition Assays (IA)

Assay-dependent

-

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host/Isotype

Armenian hamster / IgG

Class

Monoclonal

Type

Antibody

Clone

2E6

Immunogen

CD18

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.0 mg/mL

Purification

Protein G

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_223588

Product Specific Information

MA1805 targets CD18 in FACS, IA, and IP applications and shows reactivity with mouse samples.

The MA1805 immunogen is cD18.

MA1805 detects CD18 which has a predicted molecular weight of approximately 83 kDa.

This product is a Low Endotoxin formulation.

This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

Target Information

CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.